(Q54076009)

24 May 2018

title

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. (English)

1 reference

24 May 2018

author name string

Nagaya N

1

1 reference

24 May 2018

Uematsu M

2

1 reference

24 May 2018

Okano Y

3

1 reference

24 May 2018

Satoh T

4

1 reference

24 May 2018

Kyotani S

5

1 reference

24 May 2018

Sakamaki F

6

1 reference

24 May 2018

Nakanishi N

7

1 reference

24 May 2018

Miyatake K

8

1 reference

24 May 2018

Kunieda T

9

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 October 1999

1 reference

24 May 2018

Journal of the American College of Cardiology

published in

1 reference

24 May 2018

volume

34

1 reference

24 May 2018

issue

4

1 reference

24 May 2018

page(s)

1188-1192

1 reference

24 May 2018

Primary pulmonary hypertension. A national prospective study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Oral hydralazine therapy for primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Orally active prostacyclin analogue in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Reliability of the determination of cardiac output in man by means of the Fick principle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

10.1016/S0735-1097(99)00312-5

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018